Loading
Genedrive PLC Stock: price and insider trades · United Kingdom
1 insider bought shares over the last 90 days, the latest filed 02 Sept 2026.
Genedrive PLC: what insiders have been doing
Every trade that managers of Genedrive PLC disclose to RNS (LSE) is tracked on this page. From 18 October 2025 to 18 October 2026, the disclosure feed for Genedrive PLC logged 1 filing by 1 insider.
Not one open-market sale was filed. On the buying side, 1 insider reported 1 purchase. The totals exclude 1 filing filed without an amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. On the buying side, the filings list 1 chief executive among the declarants.
The last insider purchase was made public on 2 September 2026, 45 days ago.
Across the 834 companies tracked on its exchange, the median is 6 filings; at 1 filing, this issuer sits below that mark. Our records for Genedrive PLC go back to 2024, with 3 purchases and no sales on the open market in total.
Every figure here comes from the filings published by RNS (LSE) and describes the past, not future prices; it is not investment advice.
Insider Decl.
4
Thresholds
n/a
Buy Volume
€66,217
3 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySale1. Dr Gino Miele 2. Russ Shaw1 buy
1. Dr Ian Gilham 2. Dr Gino Miele 3. Russ Shaw 4. Patrick Breen 5. Tom Lindsay1 buy
Since the insiders bought
- -14.5%Entry £0.01 · Close at T+30 £0.01
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended June 2025 · cache
£0.01
Analyst consensus
Income statement
Revenue£764k
EBITDA-£5.4M-701% margin
Net income-£5.2M-684.7% margin
Valuation
Beta0.90
Balance sheet & cash
Market cap£18.5M
Free Cash Flow-£5.2M
Profitability & ownership
ROE-402.5%
ROA-117.8%
% insiders45.0%
% institutions1.2%
Last declaration on 2 September 2026
Declarations4 total
700,000,700,000 sharesLondon Stock Exchange, AIM Market (XLON)ISIN GB00B1VKB244RNS:9747220
Canonical exit: 26 Nov 2026 (T+90)
0100.0% of flowLondon Stock Exchange, AIM Market (XLON)ISIN GB00B1VKB244RNS:5477183
Canonical exit: 20 Mar 2025 (T+90)
1,000,000 shares@ £0.031100.0% of flowLondon Stock Exchange, AIM Market (XLON)ISIN GB00B1VKB244RNS:5310777
Canonical exit: 12 Nov 2024 (T+90)
◆
0Outside a trading venue - shares to be admitted to AIM market of London Stock Exchange plc on exercise of optionsISIN GB00B1VKB244RNS:5058309
4 of 4 declarations
About Genedrive PLC
Genedrive PLC is a UK-based company focused on developing genetic tests for medical diagnostics. It aims to provide innovative solutions to enhance healthcare.
